Alumis Inc. Company Profile
NASDAQ: ALMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Alumis at a glance
Alumis Inc. (NASDAQ: ALMS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in South San Francisco, CA. Alumis is led by Mr. Martin Babler Ph.D. and employs about 237 people. The company's shares have traded publicly since 2024.
At a market capitalization of $902.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001847367, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Alumis do?
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Business description based on the company's public filings.
Company information
- Legal name
- Alumis Inc.
- Ticker
- NASDAQ: ALMS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Martin Babler Ph.D.
- Employees
- 237
- Headquarters
- 280 East Grand Avenue, South San Francisco, CA, United States
- Phone
- 650 231 6625
- Website
- alumis.com
- IPO year
- 2024
- Market cap
- $902.16M
- SEC CIK
- 0001847367
Companies similar to Alumis
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MLTXMoonLake Immunotherapeutics Class A | 10.58 | -1.76% | $900.43M | vs ALMS |
| JBIOJade Biosciences Inc. | 14.15 | +2.76% | $899.90M | vs ALMS |
| RIGLRigel Pharmaceuticals Inc. | 48.72 | +1.52% | $910.08M | vs ALMS |
| KURAKura Oncology Inc. | 10.52 | -1.41% | $935.87M | vs ALMS |
| ANROAlto Neuroscience Inc. | 24.03 | +2.17% | $942.99M | vs ALMS |
| CRVSCorvus Pharmaceuticals Inc. | 10.21 | -1.92% | $858.87M | vs ALMS |
| CYRXCryoPort Inc. | 16.90 | -2.59% | $855.97M | vs ALMS |
| SPTXSeaport Therapeutics Inc. | 17.91 | -0.11% | $958.73M | vs ALMS |